Skip to main content
Clinical Trials/NCT05011981
NCT05011981
Active, not recruiting
Not Applicable

Hemostatic Activity Following Left Atrial Appendage Occlusion

University of Aarhus1 site in 1 country135 target enrollmentOctober 11, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Atrial Fibrillation
Sponsor
University of Aarhus
Enrollment
135
Locations
1
Primary Endpoint
Change in coagulation activity
Status
Active, not recruiting
Last Updated
2 years ago

Overview

Brief Summary

The primary objective of this study is to prospectively investigate hemostatic activity following transcatheter left atrial appendage occlusion (LAAO).

Detailed Description

This is a prospective cohort study of patients undergoing transcatheter LAAO at Aarhus University Hospital. Hemostatic consequences following device implantation will be evaluated using blood samples collected pre- and post-procedurally, and serially during three months follow-up in 135 LAAO patients. Platelet function and characteristics, overall activation of the extrinsic coagulation pathway and the intrinsic contact activation pathway, as well as endothelial response to implantation, will be assessed through a wide range of biochemical analyses. Patients will serve as their own controls, with a final control blood sample collected at three-months follow-up.

Registry
clinicaltrials.gov
Start Date
October 11, 2021
End Date
December 2024
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age \> 18 years
  • Atrial fibrillation (paroxysmal, persistent, or permanent)
  • Admitted and eligible for LAAO
  • Signed written consent

Exclusion Criteria

  • Known hereditary bleeding disorders (i.e. Hemophilia A and B, Von Willebrand disease)
  • Platelet count \< 75 x 109/ml

Outcomes

Primary Outcomes

Change in coagulation activity

Time Frame: 7 days, 14 days, 90 days

Coagulation activity as measured by prothrombin fragment 1+2

Secondary Outcomes

  • Non-procedural bleeding events(7 days, 14 days, 90 days)
  • Additional measures of changes in coagulation and contact activation(7 days, 14 days, 90 days)
  • Radiographical evidence of device endothelization(7 days, 14 days, 90 days)
  • Change in platelet activity(7 days, 14 days, 90 days)
  • Change in endothelial activation and response(7 days, 14 days, 90 days)
  • Radiographically confirmed device-related thrombosis(7 days, 14 days, 90 days)

Study Sites (1)

Loading locations...

Similar Trials